Pipeline and R&D programs*

In 2014, Ipsen’s R&D expenditure totaled close to €187 million, representing about 15% of Group sales.

Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs for the lifecycle management of products already marketed by the group (new formulations, extension of indications and registration of products in new geographical areas).

 Phase IPhase IPhase IIPhase III
Neurology

LRRK2

Parkinson’s disease (Partnership with Oncodesign)
In progress

Novel botulimum toxins

In progress

BN82451

Treatment of motor symptoms in Huntington’s disease 
In progress

VSN16R

Spasticity in multiple sclerosis (conducted by Canbex)
In progress

DYSPORT®

Neurogenic detrusor overactivity
Completed in 2014

DYSPORT®

Upper limb spasticity in children
In progress

Dysport®

Upper limb spasticity in adults
Completed in 2014

DYSPORT® NEXT GENERATION

Cervical dystonia
Completed in 2014

DYSPORT®

Lower limb spasticity in children
Completed in January 2015

DYSPORT®

Lower limb spasticity in adults
Completed in January 2015
Endocrinology

ACTH receptor antagonists

Cushing’s disease
In progress

Novel peptide projects

In progress

Chimeric somatostatin and dopamine agonist

Bib functional pituitary adenoma and Cushing’s disease
In progress

Somatuline®

Control of carcinoid syndrome in neuro-endocrine tumors
Completed in 2014
Urology-Oncology

Novel peptide projects

In progress

Tasquinimod

In hepatocellular carcinoma
In progress

TASQUINIMOD

Maintenance therapy after chemotherapy in prostate cancer
Stopped in April 2015

Tasquinimod

In ovarian, renal cell and gastric cancers
Completed in 2014

TASQUINIMOD

Metastatic castration-resistant prostate cancer (conducted by Active Biotech)
Completed in April 2015

TASQUINIMOD

Metastatic castration-resistant prostate cancer (China)
Stopped in April 2015

Telotristat etiprate

Carcinoid syndrome (conducted by Lexicon)
In progress

Decapeptyl®

Combined hormonal therapy for premenopausal breast cancer (conducted by IBCSG)
Completed in 2014

DECAPEPTYL®

Pamoate administration by subcutaneous route
Completed in 2014

* Last update : April 17 2015